Funding Opportunity RFA-NS-21-006 from the NIH Guide for Grants and Contracts. This funding opportunity announcement invites research on the mechanism(s) by which abnormal proteins spread throughout the nervous systems of patients with Frontotemporal Dementia and/or Lewy Body Dementia. Applications that move beyond a focus on one mechanisms of spread to consider how spreading might proceed in the context of multiple proteinopathies, multiple cell/circuit types, and multiple pathways are of particular interest.

Notice NOT-HD-20-007 from the NIH Guide for Grants and Contracts

Individuals with experience in sequencing and single-cell analysis are highly desired. Perform immunology and cancer immunotherapy experiments from design…
From Medical College of Wisconsin - Thu, 06 Aug 2020 15:09:46 GMT - View all Milwaukee, WI jobs

Funding Opportunity RFA-OD-20-023 from the NIH Guide for Grants and Contracts. This FOA seeks to support innovative research to develop novel, new or unique and non-traditional approaches (e.g. diagnostic and prognostic biomarkers and/or biosignatures) to identify and characterize the spectrum of SARS CoV-2 associated illness, including the multisystem inflammatory syndrome in children (MIS-C) and, through a prognostic algorithm, predict the longitudinal risk of disease severity after a child is exposed to and may be infected with SARS-CoV-2 to properly tailor his or her management and optimize health outcomes.

Funding Opportunity RFA-OD-20-022 from the NIH Guide for Grants and Contracts. NIH is issuing this RFA in response to the declared public health emergency issued by the Secretary, HHS, for 2019 Novel Coronavirus (COVID-19). This emergency NOSI from the NIH provides an expedited funding mechanism as part of the Rapid Acceleration of Diagnostics-Radical (RADx-rad) initiative. The goal of RADx-rad initiative is to encourage the development of novel, non-traditional approaches to identify the current SARS-CoV-2 virus or other markers of the COVID-19 disease that can be used in future outbreaks of COVID-19 and that could be applicable to other, as yet unknown, viruses. Specifically, the goal of this RFA is to solicit proposals to enhance the utility of chemosensory testing as a COVID-19 screening tool by using objective tests to examine the onset and prognostic value of chemosensory loss and to encourage the development and/or deployment of home-based and on-site chemosensory tests. The funding for this initiative is provided from the Paycheck Protection Program and Health Care Enhancement Act, 2020.

Funding Opportunity RFA-OD-20-021 from the NIH Guide for Grants and Contracts. The goal of this RFA is to solicit Fast Track STTR proposals for development of novel, non-traditional, approaches to identify the current SARS-CoV-2 virus or other biomarkers of the COVID-19 disease for use in outbreaks of COVID-19, as well as for use in future pandemics resulting from unknown viruses. This FOA is seeking applications for innovative portable devices able to produce reliable associations between biomarkers emanating from skin and the oral cavity to patients with symptomatic and asymptomatic COVID-19. Specifically, biosensing devices are expected to target skin or the oral cavity as sampling sites. Skin biosensing must detect volatile organic compounds (VOCs, i.e. scents or odors) emanating from skin in passive and noninvasive manner for use at the point of care. Oral biosensing technologies may target a wealth of biological, chemical (e.g., VOCs) and physical biosignatures representative of COVID-19 that can be sampled from exhaled breath/droplets, saliva, and tissues in the oral cavity.

Funding Opportunity RFA-OD-20-020 from the NIH Guide for Grants and Contracts. The goal of this RFA is to solicit direct to Phase II SBIR proposals for development of novel, non-traditional, approaches to identify the current SARS-CoV-2 virus or other biomarkers of the COVID-19 disease for use in outbreaks of COVID-19, as well as for use in future pandemics resulting from unknown viruses. This FOA is seeking applications for innovative portable devices able to produce reliable associations between biomarkers emanating from skin and the oral cavity to patients with symptomatic and asymptomatic COVID-19. Specifically, biosensing devices are expected to target skin or the oral cavity as sampling sites. Skin biosensing must detect volatile organic compounds (VOCs, i.e. scents or odors) emanating from skin in passive and noninvasive manner for use at the point of care. In addition to VOCs, oral biosensing technologies may target a wealth of biological, chemical and physical biosignatures representative of COVID-19 that can be sampled from exhaled breath/droplets, saliva, and tissues in the oral cavity. Leveraging the accessibility of human skin and the oral cavity, this FOA seeks 1) to advance novel biosensing technologies that are innovative, safe, and effective, and 2) to implement such technologies into devices with integrated artificial intelligent (AI) systems for the detection, diagnosis, prediction, prognosis and monitoring of COVID-19 in clinical, community and everyday settings. For skin monitoring, the device can include Electronic-nose (E-nose) technology or Gas Chromatography (GC). Thus, we are calling this program, the SCENT (Screening for COVID-19 by E-Nose Technology). Biosensing devices for the oral cavity can be technologies that have been thoroughly characterized as safe and effective in preclinical studies. Non-invasive, real-time, continuous or periodic measurements of VOCs and other biomarkers in breath, and emanating from oral tissues as signatures of onset, progression, and resolution of COVID-19 are desirable.

Funding Opportunity RFA-OD-20-019 from the NIH Guide for Grants and Contracts. NIH is issuing this FOA in response to the declared public health emergency issued by the Secretary, HHS, for 2019 Novel Coronavirus (COVID-19). This emergency FOA provides an expedited funding mechanism as part of the Rapid Acceleration of Diagnostics-Radical (RADx-rad) initiative. Specifically, this FOA seeks to fund a single cooperative agreement for a Data Coordination Center (DCC) to serve as a communication center and data hub for RADx-rad awardees. The funding for this award is provided from the Paycheck Protection Program and Health Care Enhancement Act, 2020.

Funding Opportunity RFA-OD-20-018 from the NIH Guide for Grants and Contracts. In response to the declared public health emergency issued by the Secretary, Department of Health and Human Services (DHHS) for the 2019 Novel Coronavirus (COVID-19), the National Institutes of Health (NIH) has launched the Rapid Acceleration of Diagnostics (RADx) project. This emergency funding opportunity announcement (FOA) from NIH provides an expedited funding mechanism as part of the Rapid Acceleration of Diagnostics-Radical (RADx-rad) initiative for the development of novel, non-traditional approaches to identify the current SARS-CoV-2 virus or other markers of the COVID-19 disease that can be used in future outbreaks of COVID-19 and that could be applicable to other, as yet unknown, viruses. Specifically, this FOA seeks to use developed technologies for single vesicle or exosome isolation and analysis and reposition these technologies for the detection of SARS-CoV-2. The funding for this initiative is provided from the Paycheck Protection Program and Health Care Enhancement Act, 2020. NIH requires that all projects funded under this FOA will actively coordinate, collaborate, and share data with the RADx-rad Data Coordinating Center, as allowed, and with considerations under tribal IRB processes, as appropriate. Researchers applying to this funding opportunity are strongly encouraged to review the companion Data Coordinating Center (DCC) funding opportunity announcement.

Funding Opportunity RFA-OD-20-017 from the NIH Guide for Grants and Contracts. The National Institutes of Health (NIH) is issuing this funding opportunity announcement (FOA) in response to the declared public health emergency issued by the Secretary, Department of Health and Human Services (DHHS), for the 2019 Novel Coronavirus (COVID-19). This emergency FOA provides an expedited funding mechanism as part of the Rapid Acceleration of Diagnostics-Radical (RADx-rad) initiative. The goal of this initiative is to solicit applications for the development of novel, non-traditional approaches to identify the current SARS-CoV-2 virus or other biomarkers of the COVID-19 disease for use in outbreaks of COVID-19, as well as for use in future pandemics resulting from new and emerging viruses. Specifically, this FOA is seeking applications for a portable sensing device to detect volatile organic compounds (VOCs, i.e., scents or odors) emanating from skin or exhaled breath, saliva and different oral tissues from the oral cavity. These sensing devices must be able to associate VOC patterns to patients with symptomatic and asymptomatic COVID-19.

Funding Opportunity RFA-OD-20-016 from the NIH Guide for Grants and Contracts. NIH is issuing this Funding Opportunity Announcement (FOA) in response to the declared public health emergency issued by the Secretary, HHS, for 2019 Novel Coronavirus (COVID-19). This emergency FOA provides an expedited funding mechanism as part of the Rapid Acceleration of Diagnostics-Radical (RADx-rad) initiative.

Funding Opportunity RFA-OD-20-015 from the NIH Guide for Grants and Contracts. As one of the programs within the NIH Rapid Acceleration of Diagnostics-Radical (RADx-rad) program (https://www.nih.gov/research-training/medical-research-initiatives/radx/radx-programs#radx-rad), the RADx-rad Wastewater Detection of SARS-COV-2 (COVID-19) FOA will support wastewater-based testing (WBT) surveillance which can provide detailed mapping of the extent and spread of COVID-19. Wastewater testing has been shown to be orders of magnitude less expensive and faster than clinical screening, albeit serving as a complementary approach rather than substituting individual-level testing and screening. The purpose of this FOA is to solicit cooperative agreements both for field studies and for technology research and development projects capitalizing on partnerships with small business entities in the field of WBT, to address topics such as: investigation and demonstration of specific approaches aiming to inform and optimize sample collection; implementation and development of optimized approaches to extrapolate estimation of population-level data within the community; development of optimized intervention strategies, and incorporation of computational, statistical, and mathematical models to facilitate early detection of hotspots of virus spread. The funding for this initiative is provided from the Paycheck Protection Program and Health Care Enhancement Act, 2020.

Funding Opportunity RFA-OD-20-014 from the NIH Guide for Grants and Contracts. NIH is issuing this FOA in response to the declared public health emergency issued by the Secretary, HHS, for 2019 Novel Coronavirus (COVID-19). This emergency funding opportunity announcement (FOA) from the National Institutes of Health (NIH) provides an expedited funding mechanism as part of the Rapid Acceleration of Diagnostics-Radical (RADx-rad) initiative. The goal of this RFA is to solicit proposals for the development of novel, non-traditional approaches to identify the current SARS-CoV-2 virus or other markers of the COVID-19 disease that can be used in future outbreaks of COVID-19 and that could be applicable to other, as yet unknown, viruses. Specifically, this RFA will support the early stage development of an innovative platform that integrates aptamer biosensing with touchscreen or other digital devices to achieve real-time detection and tracing of SARS-CoV-2. The project needs to demonstrate proof-of-concept of SARS-CoV-2 detection with high sensitivity and specificity, immobilized sensor functionality, automatic signal transduction and detection by digital devices. The funding for this initiative is provided from the Paycheck Protection Program and Health Care Enhancement Act, 2020. NIH expects that all projects funded under this FOA will actively coordinate, collaborate, and share data with the RADx-rad Data Coordinating Center, as allowed, and with considerations under tribal IRB processes, as appropriate. Researchers applying to this funding opportunity are strongly encouraged to review the Data Coordinating Center (DCC) funding opportunity

Notice NOT-OD-20-152 from the NIH Guide for Grants and Contracts

Notice NOT-OD-20-159 from the NIH Guide for Grants and Contracts

Competitive: Charles River: For 70 years, Charles River employees have worked together to assist in the discovery, d Michigan (US)

Notice NOT-OD-20-149 from the NIH Guide for Grants and Contracts

Competitive Salary: CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences: The Winter laboratory at CeMM, the Research Center for Molecular Medicine of the Austrian Academy.... Vienna, Austria

Competitve: CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences: The Winter laboratory at CeMM, the Research Center for Molecular Medicine of the Austrian Academy.... Vienna, Austria

Notice NOT-HL-20-810 from the NIH Guide for Grants and Contracts